唑来膦酸治疗骨量减少女性后骨折预防持续时间的观察性随访:一项6年随机对照试验延长至10年
本研究为6年随机对照试验的4年观察性随访,纳入762例曾接受4剂静脉唑来膦酸且完成核心试验6年随访的骨量减少绝经后女性。结果显示,末次输注后1.5-3.5年内骨折率降低基本维持,但此后未能维持;非椎体骨折率从核心试验最后2年的每1000人年15例增至第8-10年的42例。
要点
- 唑来膦酸降低骨折率的作用在末次输注后1.5-3.5年内基本维持,此后未维持。
- 非椎体骨折率从核心试验最后2年的每1000人年15例增至第8-10年的42例。
- 延长随访期间未发生颌骨坏死或非典型股骨骨折。
核心结论
- 核心试验中唑来膦酸降低的骨折率在末次输注后1.5-3.5年内基本维持,但此后未维持。
研究设计与样本
- 研究为6年随机对照试验的4年观察性随访,在奥克兰招募的2000例65岁以上、全髋或股骨颈T值-1.0至-2.5的社区绝经后女性中,纳入762例曾接受4剂静脉唑来膦酸且完成核心试验6年随访者。
- 随访期间进一步治疗由参与者自己的医生决定,参与者报告新发骨折,并在7.5年和9.0年电话更新健康状况,10.0年受邀现场访视。
主要发现
- 非椎体骨折率从核心试验最后2年的每1000人年15例(95%CI 10-21)增至第6-8年的24例(17-33)和第8-10年的42例(32-53),与核心试验最后2年安慰剂组相似。
- 第6年全髋骨密度(每0.1 g/cm2相对风险0.73,95%CI 0.57-0.93;p=0.011)和非椎体骨折史(1.74,1.12-2.69;p=0.013)预测新发骨折,但全髋骨密度变化未预测。
- 延长随访期间全髋骨密度从较研究基线高4.2%降至高0.8%(p<0.0001)。
- 骨转换标志物对预测个体骨密度丢失无用,且任何参与者均未发生颌骨坏死或非典型股骨骨折。
关键数值与推荐
- 非椎体骨折率:核心试验最后2年每1000人年15例(95%CI 10-21),第6-8年24例(17-33),第8-10年42例(32-53)。
- 第6年全髋骨密度每0.1 g/cm2相对风险0.73(95%CI 0.57-0.93;p=0.011),非椎体骨折史相对风险1.74(95%CI 1.12-2.69;p=0.013)。
- 延长随访期间全髋骨密度从较基线高4.2%降至高0.8%(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. METHODS: Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral neck in the range -1·0 to -2·5, we invited participants who received four doses of intravenous zoledronate, completed follow-up to year 6 of the core trial, did not have metabolic bone disease (other than osteoporosis), and were not using bone-active drugs into this 4-year observational study extension, during which further treatment was at the discretion of their own doctors. Participants were asked to notify study staff of any new fractures and were telephoned at 7·5 years and 9·0 years to update their health status. Participants were then invited to an onsite visit at 10·0 years. Fractures and other health events were documented at each contact and analysed in all women who entered the extension, and bone mineral density (BMD; analysed in participants without notable use of bone-active medications who attended an onsite visit at 10 years) and turnover markers (measured from fasting morning blood in a random subset of 50 participants) were measured at year 10. FINDINGS: Of the 1000 women randomly assigned to receive zoledronate in the core trial, 796 participants were eligible for the extension, of whom 762 (96%) entered the extension between Sept 24, 2015, and Dec 13, 2017. Mean follow-up duration was 4·24 years (SD 0·57, range 0·61-6·55; final follow-up on May 25, 2022). 727 (91%) of participants were assessed at 10 years. 25 women died during the extension, six withdrew for medical reasons, and four were lost to follow-up. 92 women suffered 114 non-vertebral fractures during the extension. Non-vertebral fracture rates increased from a nadir of 15 fractures per 1000 woman-years (95% CI 10-21) in the last 2 years of the core trial to 24 fractures (17-33) in years 6-8 and 42 fractures (32-53) in years 8-10, similar to that in the placebo group in the last 2 years of the core trial. Total hip BMD (relative risk per 0·1 g/cm2 0·73, 95% CI 0·57-0·93; p=0·011) and a previous history of non-vertebral fracture (1·74, 1·12-2·69; p=0·013) at year 6 predicted incident fractures but change in total hip BMD did not. Total hip BMD decreased from 4·2% above study baseline to 0·8% above baseline (p<0·0001) during the extension. Turnover markers were not useful for predicting BMD loss in individuals. Osteonecrosis of the jaw or atypical femoral fractures did not occur in any participants. INTERPRETATION: The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5-3·5 years after the last zoledronate infusion, but not thereafter. FUNDING: Health Research Council of New Zealand.
引用
- Reid IR, Horne AM, Mihov B, et al. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years. Lancet Diabetes Endocrinol. 2024. PMID: 38452783. doi:10.1016/S2213-8587(24)00003-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。